PPP2R1A and cancer: Compared with the direct use of shRNAs against Ppp2r1a in cancer cell lines, the reduced anti-cancer effect observed in systemic administration of LB-100 may be attributed to the lower concentration of LB-100 in the tumour site, which should be improved by controlled delivery of therapeutic agents to tumours.